- Febuxostat Intermediates
-
- $0.00 / 25Kg/Bag
-
2024-04-22
- CAS:160844-75-7
- Min. Order: 2Kg/Bag
- Purity: 99% up, High Density
- Supply Ability: 20 tons
|
| | Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate Basic information |
| Product Name: | Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate | | Synonyms: | 5-Thiazolecarboxylicacid, 2-[3-cyano-4-(2-Methylpropoxy)phenyl]-4-Methyl-, ethyl ester;2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate;ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl;Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate;Ethyl> 2-(3-cyano-4-isobutoxyphenyl)-4-Methyl-5-th;5-carboxylato-2-[3-cyano-4-(2-Methylpropoxy)phenyl]-1-ethyl-4-Methyl-1H-1$l^{4},3-thiazol-1-yl;ethyl ester of febuxostat;2-[3-cyano-4-(2-Methylpropoxy)phenyl]-4-Me | | CAS: | 160844-75-7 | | MF: | C18H20N2O3S | | MW: | 344.43 | | EINECS: | 927-913-5 | | Product Categories: | Febuxostat Intermediates;Febuxostat intermediate | | Mol File: | 160844-75-7.mol |  |
| | Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate Chemical Properties |
| Melting point | 176 °C | | Boiling point | 497.1±55.0 °C(Predicted) | | density | 1.22 | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO (Slightly, Heated), Methanol (Very Slightly, Heated) | | form | Solid | | pka | 1.02±0.10(Predicted) | | color | White to Off-White | | InChI | InChI=1S/C18H20N2O3S/c1-5-22-18(21)16-12(4)20-17(24-16)13-6-7-15(14(8-13)9-19)23-10-11(2)3/h6-8,11H,5,10H2,1-4H3 | | InChIKey | OGAZOYHQFBSRMC-UHFFFAOYSA-N | | SMILES | S1C(C(OCC)=O)=C(C)N=C1C1=CC=C(OCC(C)C)C(C#N)=C1 | | CAS DataBase Reference | 160844-75-7(CAS DataBase Reference) |
| | Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate Usage And Synthesis |
| Chemical Properties | White crystalline powder | | Uses | Ethyl 2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate is an impurity of Febuxostat (F229000), a xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout. | | Synthesis |
CarboxylatePotassium carbonate (300 g, 2.17 mol) and isobutyl bromide (142.7 g, 1.041 mol) were added to a solution of ethyl-2-(3-cyano-4-hydroxyphenyl)-4-methyl-5-thiazole carboxylate (100 g, 0.347 mol) in dimethylformamide (300 mL), and the reaction mixture was heated at a temperature of about 75°C for about 8 hours. After completion of the reaction, the reaction mixture was cooled to about 40°C, and water was added. The reaction mixture was further cooled to about 0°C and stirred for about 1 hour. The solid thus obtained was filtered, washed with water, and dried to give Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate. (Yield: 11 lg, 92.9%)
|
| | Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate Preparation Products And Raw materials |
|